From pre-pregnancy planning to advanced genetic analysis, explore services suited to your needs.
NIPT (Non-Invasive Prenatal Screening) is a safe prenatal screening test performed from the 10th week of pregnancy using a single tube of maternal blood. It helps assess the baby's risk for common chromosomal differences, particularly Down syndrome, at an early stage. No invasive procedure is applied to mother or baby. NIPT is a screening test, not a diagnostic test.
By analyzing hereditary cancer risks and tumor-specific genetic alterations, we contribute to early diagnosis and the evaluation of personalized treatment options.
In IVF treatment, we screen embryos prior to transfer to enable the selection of healthy embryos and prevent the transmission of hereditary disorders.
The potential effects of medications, radiological procedures, chemicals, and environmental exposures before or during pregnancy are individually evaluated. Teratology consultation provides evidence-based risk assessment for mother and fetus considering timing, dosage, and gestational age.
For couples planning or in consanguineous marriages, family medical history, inherited disorders, and potential reproductive risks are comprehensively evaluated by clinical specialists.
Scientific developments in genetics and the latest news from our center.
Prof. Dr. Zeynep Ocak was awarded the Science Honor Award by the Azerbaijan Ministry of Defense and the TÜBİTAK Science Board due to joint scientific projects and studies of the two countries.
Despite their massive size and long lifespans, elephants have much lower cancer rates than humans. In this article, we examine the role of the TP53 gene, known as the guardian of the genome, and Peto's Paradox.
At the Turkey Prestige Awards 2024, ECEGEN was awarded the “Most Successful Center of the Year” with its Artificial Intelligence Studies in Cancer Genetics.
A guide to FMF and recurrent fever and pain: the role of MEFV, the limitations of genetic testing, inheritance and regular follow-up.
A personalized mRNA vaccine produced long-lasting immune responses against pancreatic cancer in an early clinical study. Although encouraging, the approach remains experimental.
GLP-1 medicines can influence appetite and blood sugar regulation, but they are not suitable for everyone. We explain their effects, limitations, and why medical supervision matters.
A personalized gene-editing therapy was developed in about six months for a baby with a rare metabolic disease. Here is what this first case shows—and why it remains experimental.
The first FDA-cleared blood test for evaluating Alzheimer's disease may simplify part of the diagnostic pathway. It is not intended for screening or for making a diagnosis on its own.
An experimental gene therapy produced hearing gains in children with profound hearing loss caused by two disease-causing OTOF variants. The approach is promising but applies only to a specific genetic subtype.
Serving as the gold standard for detecting chromosomal anomalies and structural rearrangements, our conventional and molecular cytogenetics workflows operate under rigorous international quality standards in sterile cleanrooms.
Medical Genetics Specialist Prof. Dr. Zeynep Ocak highlighted the decisive power of comprehensive genetic analyses in disease prevention, early diagnosis, and personalized therapy.
As of 01.11.2024, ECEGEN has been accredited according to TS EN ISO 15189:2023 standard, registering its leadership in patient safety, accuracy, and quality.
Prof. Dr. Zeynep Ocak was honored with the Honorary Professorship Diploma by the VEKTOR International Science Center at the ceremony held in Baku on August 19, 2022.
Highlights from the seminars, symposiums and awareness programs where we bring scientific knowledge together with the community.
A selection of ECEGEN's television broadcasts, interviews, and scientific talks. You can watch them directly here.
You can reach our laboratory team directly for any information you need about test selection, the sample collection process, and clinical genetic counselling.
